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The real impact of biological therapy (anti-TNF agents) in abdominal operations secondary to
Crohn’s disease is a matter of debate in the international literature. Several studies demon-
strated that there can be an increase in postoperative complications in patients previously
treated with these agents. On the other hand, the majority of studies published over the
last years question this effect, and did not demonstrate any relationship between biologics
and  outcomes related to surgical postoperative complications. Some meta-analyses were
published, with different outcomes and different conclusions. Experimental studies in ani-
mals were also recently published, with opposite results, despite similar methodology. In
this  review, the authors resume all the relevant papers in the international literature with
respect to the theme, and demonstrate the heterogeneity of the studies, as well as the dis-
parity of their results and outcomes. The real impact of anti-TNF agents on postoperative
complications in Crohn’s disease is still controversial, and needs to be better elucidated.
Controlled trials must be performed to better address this issue.
©  2015 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. All
rights reserved.
Impacto  dos  anti-TNF  nas  complicac¸ões pós-operatórias  na  doenc¸a de
Crohn:  uma  revisão
Palavras-chave:
Doenc¸a de Crohn
r  e  s  u  m  o
O real e verdadeiro impacto da terapia biológica, constituída por inibidores do fator de
necrose tumoral (TNF) alfa, em operac¸ões abdominais na doenc¸a de Crohn, ainda é exten-
Fator de necrose tumoral-alfa
Cirurgia colorretal
samente debatido na literatura. Há muitos estudos que referem aumento da possibilidade
de  complicac¸ões em pacientes tratados previamente com esses agentes. Por outro lado, há
uma série maior de trabalhos que questionam esse aumento, não demonstrando qualquer
impacto dessas drogas nos desfechos pós-operatórios. Algumas metanálises foram publi-
cadas, com resultados ligeiramente diversos. Trabalhos experimentais em animais foram
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recentemente realizados, igualmente com resultados opostos, apesar de metodologia
semelhante. Nessa revisão, os autores discorrem sobre todos os trabalhos relevantes na
literatura nacional e internacional sobre o tema, e demonstram a heterogenicidade dos
mesmos, bem como a disparidade dos resultados e desfechos. O real impacto dos agentes
anti-TNF sobre operac¸ões abdominais na doenc¸a de Crohn ainda é controverso, e precisa ser
melhor elucidado. Estudos controlados devem ser realizados para melhor elucidac¸ão dessa
questão.
©  2015 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
Todos os direitos reservados.
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tors for infections. On the other hand, in the multivariate
analysis only the concomitant preoperative use of biologi-
cals with corticosteroids was considered as a risk factor forntroduction
n recent years, remarkable progress in the medical treat-
ent of Crohn’s disease (CD) was achieved, particularly with
he advent of tumor necrosis factor (TNF) inhibitors.1,2 The
linical response to these drugs has been demonstrated in
ome randomized trials and, subsequently, other studies have
hown reduction in hospitalizations and surgeries and a con-
equent change in the natural history of the disease, with
he possibility of preventing complications in some sub-
roups of responders.3,4 Inﬂiximab (IFX) was the ﬁrst anti-TNF
rug approved for CD, and knowledge on this drug in the
anagement of patients was consolidated by more than 14
ears of clinical experience.5 Subsequently, in 2007, a sec-
nd biological agent of TNF-inhibitor class was approved by
egulatory agencies for CD therapy, adalimumab (ADA). More
ecently, a third biologic drug, certolizumab pegol (CTZ), was
pproved as an option for CD therapy. These agents con-
titute what is known today as biological therapy in the
anagement of CD. Its use is growing exponentially, and
urrently, these biologicals are considered the most effec-
ive drugs in the medical management of moderate to severe
isease.5
The indications for biological treatment in CD are directed
ainly for severe forms of this disease,3,4 and frequently
 surgical treatment will be indicated during the use of
hese drugs.5 As these drugs are potent immunosuppressants,
here is an obvious concern, if this reduction in the defenses
omente, retirar body’s could lead to greater possibilities of
urgical and infectious complications in the postoperative
eriod of a bowel resection in CD patients. There is also con-
roversy on the effects of these agents at tissue level, in bowel
nastomosis healing process. Data from the literature are
onﬂicting, and retrospective studies of case series showed
qually conﬂicting conclusions.
Against this scenario of doubt, where there really exists
nsecurity of surgeons in operating patients previously
xposed to biological agents, it is critical to elucidate the
elationship between these drugs and the rates of surgi-
al and medical complications in the postoperative period
fter intestinal resections in CD. There is a notable lack of
olid and consistent data on the subject. Hence, this sce-
ario justiﬁes the conduction of this review, in order to
erify, through a full search of the literature, information on
he actual outcome related to complications after abdomi-
al surgery in CD patients with prior exposure to biological
herapy.Clinical  studies  with  a trend  for  further
postoperative  complications  with  the  use  of
biologicals
A study conducted at the Cleveland Clinic in Ohio (United
States), published in 2008, compared the effects of IFX in
patients undergoing ileocolectomy for CD into 3 groups:
operated patients without IFX in pre-biological era, patients
in the era after drug commercialization, and patients pre-
viously exposed to IFX before surgery. Retrospectively, 60
patients operated with prior exposure to IFX within 3 months
before the procedure showed higher risk of sepsis, abdom-
inal abscesses, re-admissions and anastomotic dehiscence.
The authors also suggested that proximal diversion stomas
were protective factors in relation to these higher risks, and
could be recommended in patients with previous use of this
medication.6
Rizzo et al., in an Italian single-center retrospective study,
analyzed the surgical outcomes in 114 patients with CD and
ulcerative colitis, with prior exposure to anti-TNF agents
(n = 54) compared to a control group without use of these drugs
(n = 60). With no distinction between the type of inﬂammatory
disease, the authors concluded, in an univariate analysis, that
infectious complications were more  frequent in individuals
previously treated with biologicals (60% versus 13%; p = 0.023).
However, in a multivariate analysis, an increase in postopera-
tive complications related to previous use of biologicals were
not found. Only high doses of corticosteroids have been linked
to higher rates of infection.7
In a meta-analysis published in 2012, Kopylov et al. ana-
lyzed eight studies on the subject, all included in this review,
with a total of 1641 patients. After the pooled analysis of data
from these studies, the authors concluded that there was a
greater risk of infectious complication rates in patients pre-
viously treated with IFX, predominantly not related to the
surgical site. They also found a tendency (not statistically
conﬁrmed) toward an increase in the rates of overall and non-
infectious complications.8
In a French multicenter retrospective study, Serradori
et al. analyzed the levels of postoperative infections after 217
major abdominal operations secondary to CD. In a univariate
analysis, the authors found that patients older than 25 years
and with previous use of corticosteroids, of anti-TNF agents,
and of biologicals together with corticosteroids were risk fac-
j). 2 0
and possible changes caused by corticosteroids, immunosup-
pressants and biologicals on postoperative outcomes were130  j coloproctol (rio 
infectious complications (odds ratio [OR] = 8.03, 95% conﬁ-
dence interval [CI] = 1.93–33,43; p = 0.035).9
Syed et al., in 2013, published a study including patients
undergoing various types of abdominal operations, even not
related to CD. 325 operative procedures were studied in 211
patients, and 150 of these procedures were performed in
subjects with prior exposure to biological agents. In the mul-
tivariate analysis, the authors found that previous use of
TNF-alpha inhibitors (including IFX, ADA and CTZ) was a
risk factor for overall higher rates of infectious complica-
tions (OR = 2.43; 95% CI = 1.18–5.03) and surgical site infections
(OR = 1.96; 95% CI = 1.02–3.77).10
Four meta-analyses on the possible impact of anti-TNF
agents on postoperative complications in CD patients have
recently been published. Interestingly, all meta-analyzes
include virtually the same studies (all included in this liter-
ature review), and through slightly different methods, these
studies came to only slightly different conclusions. From
these meta-analyses, only one, which pooled eight studies,
pointed to a non-inﬂuence of biological therapy on postopera-
tive outcomes; this will be discussed at the next session.11
The other three meta-analyzes concluded that a negative
inﬂuence of the use of these drugs in postoperative compli-
cations in CD may exist. Narula et al. reported, after inclusion
of 18 studies and 4659 patients, that biological agents may
slightly the risk of postoperative complications, and, above
all, this can signify an analysis bias, and not the biologi-
cal effect of these drugs per se.12 El-Hussuna et al., after
including 14 studies with 679 patients exposed to biologi-
cals versus 2363 controls, concluded that, in studies with less
potential for bias, previous use of these agents increased
the risk of anastomotic dehiscence.13 Finally, Yang et al., in
their meta-analysis analyzing 18 studies and 5769 patients,
showed an association between previous use of biologicals and
complications (OR = 1.45, 95% CI = 1.04–2.02) and infectious
(OR = 1.47 95% CI = 1.08–1.99) and non-infectious (OR = 2.29,
95% CI = 1.14–4.61) complications, respectively, in the postop-
erative period. The authors suggest a modest increase in the
risk of complications in patients previously exposed to anti-
TNF agents.14
The ﬁrst prospective study on the theme “biologicals ver-
sus surgical complications” in the management of CD was
published by Lau et al. in 2014. In this study, the authors
measured IFX serum levels 7 days before the surgical proce-
dure, in an attempt to relate higher serum levels with higher
rates of complications. From a total sample of 217 patients,
123 were CD patients. Using an IFX serum level of 3 g/ml
as a cutoff point, overall (OR = 2.5, p = 0.03) and infectious
(OR = 3.0, p = 0.03) complications in the postoperative phase
were more  frequent in patients with serum levels above this
above this level. Higher rates of postoperative overall com-
plications and of re-admissions in patients with IFX levels
≥8 g/ml also were noted, compared to those subjects with
IFX levels <3 g/ml. These changes have not been conﬁrmed
in patients with ulcerative colitis submitted to surgical proce-
dures, probably due to a more  rapid washout of the drug in
these patients.15
The studies described in this review session are summa-
rized with their respective methodologies and key ﬁndings in
Table 1. 1 5;3  5(2):128–136
Clinical  studies  with  no  trend  for  further
complications  with  postoperative  use  of
biologicals
The ﬁrst study on the subject “biologicals and surgical com-
plications in CD” in the literature was carried out in the
United States in 2003. In this article, Tay et al. retrospectively
demonstrated that patients with previous use of immuno-
suppressants in its various forms and undergoing abdominal
operations secondary to CD did not show higher rates of
intra-abdominal septic complications (abscesses, dehiscence,
enterocutaneous ﬁstulas) versus subjects without associated
immunosuppression (5.6% in immunocompromised patients
versus 25% in those untreated, p <0.01). In a multivariate anal-
ysis, the authors also questioned a possible protective effect
of immunosuppression (with some patients using biological
agents), with reduced rates of complications compared to the
control group.16
Colombel et al., in 2004, published a study reporting the ﬁrst
experience of the Mayo Clinic in Minnesota, United States, for
possible consequences of perioperative use of IFX in postop-
erative complications. From a total of 270 patients undergoing
abdominal operations for CD over the time period considered
(all with intestinal resections), 52 were exposed to IFX. These
authors found no increased risk of septic complications in
patients who received IFX in the perioperative period.17
Marchal et al., in 2004, reported the experience of a Belgian
referral centre, where 40 patients previously exposed to IFX
undergoing intestinal resection had their outcomes compared
to 39 matched patients according to age and type of procedure.
The objective was to evaluate, between groups, the occur-
rence of early and late major and minor complications. These
authors did not found higher rates of complications between
groups and no difference between in in-hospital length of stay
for these patients. A trend toward a higher incidence of infec-
tions in general in the group previously exposed to IFX was
found, but without statistical signiﬁcance.18
In 2008, an american study conducted by Kunitake et al.
reported the isolated experience of an US referral center in
the management of IBD in relation to possible changes in
postoperative complication rates in patients who  have pre-
viously used IFX. From a total of 413 patients studied, only
188 had CD. In that study, patients with ulcerative colitis and
indeterminate inﬂammatory bowel disease were included. In
their paper, the authors did not clarify the exact number of CD
patients with prior use of IFX. However, they concluded that
there were no overall differences (without distinguishing the
type of inﬂammatory bowel disease) in clinical and surgical
complication rates (16.8% in the group with IFX vs. 15.7% in
control group; p = 1.0). Nevertheless, there was a higher mean
of in-hospital length of stay for the group of operated patients
who had been previously treated with IFX versus control group
(12.2 vs. 10.2 days, p < 0.0001).19
In 2009, a series of 112 CD patients operated at the Mayo
Clinic in Arizona, United States, was retrospectively described,evaluated. Of these 112 patients, only 17 used IFX prior to
their surgical procedure. Major complications were not found
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Table 1 – Major studies showing a possible negative impact of the use of biologicals in postoperative complications in CD,
with higher rates of complications.
Author Journal Year Study type Number of patients
exposed to biologicals
Observations
Appau et al. J Gastrointest Surg 2008 Single-center retrospective 60 Higher rates of sepsis,
abdominal abscesses,
readmissions and anastomotic
dehiscence.
Rizzo et al. Int J Colorect Dis 2011 Single-center retrospective 54 (Ulcerative colitis included) Higher rates of infectious
complications in univariate
analysis
Kopylov et al. Inﬂamm Bowel Dis 2012 Meta-analysis 423 Higher rates of infectious
complications not related to
the surgical site
Serradori et al. Br J Surg 2013 Multicenter retrospective 42 Concomitant use of biologicals
with corticosteroids increased
infectious complications in
multivariate analysis
Syed et al. Am J Gastroenterol 2013 Single-center retrospective 150 Higher rates of infections in
general and of surgical site
infections
Narula et al. Alim Pharmacol Ther 2013 Meta-analysis 987 (Ulcerative colitis included) Higher rates of complications
in general and of infectious
complications
El-Hussuna et al. Dis Colon Rectum 2013 Meta-analysis Not deﬁned Higher rates of anastomotic
complications in low bias
studies
Yang et al. Int J Surg 2014 Meta-analysis Not deﬁned Higher rates of complications
in general and of infectious
complications
Lau et al. Ann Surg 2014 Single-center prospective 123 Higher rates of complications
in general and of infectious
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fn users of IFX. However, the authors did found that blood loss
400 ml  (p < 0.003) and emergency surgery (p < 0.005) were the
nly risk factors for increased postoperative complications.20
Nasir et al. published in 2010 an update of the experience
f the Mayo Clinic in Minnesota (United States) on the sub-
ect, this being the ﬁrst study to include patients using ADA
nd CTZ in a series. The authors included patients presenting
ny intra-abdominal suture line, as a result of the surgical pro-
edure for CD. The results of 119 patients previously exposed
o anti-TNF agents, compared to 251 who did not use biologi-
als, were similar with respect to postoperative complications
27.9% vs. 30.1%, p = 0.63), showing no higher rates of compli-
ations in patients using anti-TNF agents prior to surgery.21
In Brazil, Kotze et al. presented in 2011, during the Crohn’s
nd Colitis Foundation of America (CCFA–USA) meeting, the
esults of a pilot sample of patients, with lack of association
etween surgical complications and previous use of biologi-
als in CD patients. 76 patients were studied, 19 of them with
rior exposure to biological agents (12 to IFX and 7 to ADA).
he rates of overall postoperative complications, anastomotic
ehiscence, urinary tract infection and pneumonia were sim-
lar between these two groups. This was the ﬁrst study on
he subject in Brazilian patients, and although published in
bstract form, showed interesting results, compatible with
hose found in most papers from the international literature.22
Canedo et al. published the results of a retrospective study
rom the Cleveland Clinic, Weston, Florida, United States. Thecomplications in patients with
detectable serum IFX
study included 225 patients undergoing bowel resection for
CD divided into 3 groups: those with previous IFX, those on
immunosuppressants and corticosteroids, and ﬁnally those
on aminosalicylates only. In this series, there were no dif-
ferences between the groups regarding pneumonia (p = 0.14),
surgical site infection (p = 0.35), abscess (p = 0.34) and anasto-
motic dehiscence (p = 0.44) rates. Thus, the authors concluded
that the previous use of IFX was not related to changes in
postoperative outcomes in patients with DC in need of major
abdominal surgery.23
El-Hussuna et al., in a Danish study that included 417
patients operated in four different hospitals, compared the
postoperative outcomes of 32 patients operated with previ-
ous use of biologicals versus 385 patients without previous use
of this agents. No higher rates of anastomotic postoperative
complications were found in the group previously exposed
to biological agents versus non-exposed group (9% vs. 12%;
p = 0.581). In this study, a multivariate analysis showed that
prior use of corticosteroids in daily doses >20 mg  and colon-
colonic anastomoses were main risk factors for anastomotic
dehiscence in CD patients.24
In a German study, Kasparek et al. analyzed the impact
of prior use of IFX in abdominal operations secondary to
CD. As methodology, these authors matched their patients
with control-cases. In each group, 48 patients with similar
demographic characteristics and minor complications were
included. No major postoperative morbidity in terms of sepsis
j). 2 0132  j coloproctol (rio 
and anastomotic complications was found between groups,
besides in-hospital length of stay. The authors suggested that
there is no need for a change in surgical strategy in CD patients
only in face of the use of IFX per se.25
Mascarenhas et al. studied possible complications sec-
ondary to ileocolic resection from a different perspective, but
also retrospectively. These authors compared the complica-
tions in 93 CD patients (19 with previous use of biological
therapy) versus 698 patients undergoing ileocolectomy for
other causes. In a subanalysis of their study, these authors
found no increase in the overall complication rate in patients
with CD with or without previous use of biologicals.26
Norgard et al., in Denmark, reported their ﬁndings in a full-
country database with over 2000 patients. The postoperative
outcomes after major abdominal surgery for CD in 214 patients
with previous use of biological agents were compared with
the outcomes from 2079 patients without exposure to these
drugs, in the largest study on the subject ever published in
literature. The authors concluded that there was no difference
in complications between the time of previous use of IFX (less
than two weeks from the date of the operation and 2–12 weeks
from the date of the procedure) versus control group. These
authors also concluded that no higher rates of reoperation,
anastomotic dehiscence and bacteremia occurred in patients
with prior use of anti-TNF agents.27
In an interesting Canadian study, Waterman et al. also
compared the effects of prior exposure to biological agents
in abdominal operations secondary to CD. In this series, 195
patients had previously used IFX or ADA (or both) in a popula-
tion of 473 patients, including patients with ulcerative colitis
and indeterminate IBD. In patients with a combination of
biologicals with immunosuppressive drugs prior to their
surgery, higher rates of urinary tract and surgical site infection
were found. The time elapsed since the last dose of the biolog-
ical agent to surgery (less than 2 weeks, 2–4 weeks and 30–180
days) did not inﬂuence postoperative complication rates. One
of the novelties of this study was the determination of serum
levels of IFX previously to the procedure, and patients with
detectable levels of the drug had early complications in similar
numbers to those with undetectable levels.28
Bafford et al. published in 2013 the Mount Sinai Hospi-
tal experience for surgical complications in 196 CD patients,
divided into 2 groups – with and without use of immunosup-
pressive drugs (including biological agents). Like many  studies
in the literature, the authors identiﬁed a higher risk of com-
plications in users of biological agents. Additionally, these
authors have not concluded in favor of an increased risk of
postoperative complications in patients previously medicated
with corticosteroids, thiopurines, or with a combination of
more  than one immunosuppressive agent.29
A meta-analysis published in 2013 by Billioud et al.
included 21 studies on the effect of biologicals in abdom-
inal surgery for IBD in general (CD and ulcerative colitis
analyzed together). The authors concluded that there was
an increased risk of infections in general in the postopera-
tive period in CD patients (OR = 1.45; 95% CI = 1.03–2.05), but
emphasized that potential inﬂuencing factors, mainly con-
comitant therapies, might not be adequately studied.30 These
results were similar to those in a meta-analysis published by
Rosenfeld et al. in 2013, who found no inﬂuence of biological 1 5;3  5(2):128–136
therapy on complications in patients from almost the same
studies.11
Also retrospectively, Krane et al. studied possible con-
sequences of IFX use in operations conducted solely by
laparoscopy. This US sample included CD and ulcerative coli-
tis patients, and 65 CD patients were operated with previous
use of IFX, and their results in terms of complications were
compared to 194 patients with the same disease and without
prior biological treatment. There was no difference between
groups regarding the conversion rates to laparotomy, over-
all complications, anastomotic dehiscence, thromboembolic
events and infections. The authors concluded, through a mul-
tivariate analysis, that there is no inﬂuence of IFX on surgical
outcomes after laparoscopic operations.31
In a Scandinavian study, Myrelid et al. studied 298 patients
from six referral centers, 111 of whom previously exposed
to the use of biologicals before surgery. The primary objec-
tive of the study was to analyze comparatively the two
groups in relation to the previous use of these drugs and
anastomotic complications. Infections in general were sec-
ondarily analyzed. The authors demonstrated that there was
no difference between groups for anastomotic complica-
tions (7.2% versus 8%; p = 0.976), postoperative complications
and infections in general. Similarly, differences in terms of
anastomotic dehiscence between groups were not found in a
multivariate analysis (OR = 0.89; 95% CI = 0.37–2.17), revealing
no relationship between previous use of biologicals and worse
postoperative outcomes.32
In a more  recent critical review, Papaconstantinou et al.,
through a systematic literature review, carefully analyzed the
most important studies discussed in this session, and using
scores of studies by MINORS criteria, were unable to reach
ﬁrm conclusions about the real impact of biological agents
on postoperative outcomes in Crohn’s disease.33 The results
of the main studies that didn’t show a possible effect of bio-
logical agents on postoperative outcomes in CD patients are
summarized in Table 2.
Experimental  studies
An interesting experimental study on the “surgery and biolog-
icals” theme was published by Lopes et al. in 2008.34 Wistar
rats, allocated into, with and without a single subcutaneous
dose of 5 mg/kg of IFX, were operated. A median laparotomy
was performed in these animals and, after euthanasia, the
tensile force required for opening the suture line in the abdom-
inal wall was measured. It was observed in this study that
rats with prior IFX needed less tensile strength to open the
suture line versus control group on days 3 and 7 after laparo-
tomy. This study suggested a potential effect of IFX on changes
in inﬂammatory and proliferative phases of wound healing,
which could have an impact on a possible increase on the rates
of anastomotic dehiscence.34
More recently, the international literature has been con-
cerned with an understanding, at the physiological and
cellular level, on the effects of anti-TNF agents in the pro-
cess of anastomosis healing, and consequently on a possible
impact on the success of the surgical outcome. Thus, some
experimental studies have recently been published.
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Table 2 – Main studies showing no difference in the rate of postoperative complications in patients with CD using
biologicals.
Author Journal Year Study type Number of patients
exposed to biologicals
Observations
Tay et al. Surgery 2003 Single-center
retrospective
72  Higher rates of intra-abdominal
septic complications not reported
Colombel et al. Am J Gastroenterol 2004 Single-center
retrospective
52  Increased risk of complications in
general or septic complications not
found
Marchal et al. Alim Pharmacol Ther 2004 Single-center
retrospective
40  Higher rates of complications and
differences in in-hospital length of
stay were not found
Kunitake et al. J  Gastrointest Surg 2008 Single-center
retrospective
101  Overall, no differences in rates of
medical and surgical complications.
However, a longer mean in-hospital
length of stay was found
Indar et al. World J Surg 2009 Single-center
retrospective
17  No major complications were
identiﬁed
Nasir et al. J Gastrointest Surg 2010 Meta-analysis 119 No higher rates of complications
were found
Kotze et al. Inﬂamm Bowel Dis 2011 Multicenter
retrospective
19  No differences in rates of
postoperative complications in
general, anastomotic dehiscence,
urinary tract infection and
pneumonia
Canedo et al. Colorectal Dis 2011 Single-center
retrospective
65  No differences in pneumonia,
surgical site infections, abscesses
and anastomotic dehiscence rates
El-Hussuna et al. Scand J Gastroenterol 2012 Multicenter
retrospective
32  No higher rates of postoperative
anastomotic complications were
observed
Kasparek et al. Inﬂamm Bowel Dis 2012 Single-center
retrospective
48  There were no major postoperative
morbidity in terms of sepsis and
anastomotic complications, besides
in-hospital length of stay
Mascarenhas et al. Am J Surg 2012 Retrospective 19 No increase in overall complication
rate in a subanalysis of the study
Norgard et al. Aliment Pharmacol Ther 2013 Multicenter
retrospective
214  There were no differences in
complications, or higher rates of
reoperation, anastomotic
dehiscence and bacteremia
Waterman et al. Gut 2013 Single-center
retrospective
195  (Ulcerative colitis e
undetermined IBD
included)
Higher rates of urinary tract
infections and in the surgical site.
Time since the last dose of biological
agent and surgery did not inﬂuence
postoperative complications.
Bafford et al. J Clin Gastroenterol 2013 Single-center
retrospective
63  No increased risk of complications
identiﬁed.
Billioud et al. J Crohns Colitis 2013 Meta-analysis 977 Increased risk of postoperative
infections overall, but the authors
could not properly study the
inﬂuence of concomitant therapies.
Rosenfeld et al. J Crohns Colitis 2013 Meta-analysis 344 There was no inﬂuence on
complications.
Krane et al. Dis Colon Rectum 2013 Single-center
retrospective
65  Increased risk of postoperative
infections overall, but the authors
could not properly study the
inﬂuence of concomitant therapies.
Myrelid et al. Br J Surg 2014 Multicenter
retrospective
111  There was no difference in
anastomotic complications,
postoperative complications and
general infections.
Papaconstantinou et al. J Gastrointest Surg 2014 Meta-analysis 1554 The authors did not reach,
consistent conclusions
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Table 3 – Main experimental studies analyzing the impact of the use of biologicals in postoperative complications in CD.
Author Journal Year Study type Number of animals
exposed to
biologicals
Observations
Lopes et al. Acta Cir Bras 2008 Experimental prospective 30 Lower tensile strength to break
suture lines; changes in
inﬂammatory and proliferative
phases of wound healing, and
may increase anastomotic
dehiscence
Papaconstantinou et al. Int J Surg 2014 Experimental prospective 28 No difference in bursting
pressure of anastomoses and
in septic complications. Less
inﬂammatory activity and
increased tissue remodeling,
without clinical consequences
Frostberg et al. BMC Surg 2014 Experimental prospective 15 No difference in tensile
strength to break suture lines
 prosp
rJensen et al. Surg Res 2014 Experimental
A study from Greece sought possible effects of IFX in
intestinal anastomoses in rats. After resection of the termi-
nal ileum in their animals, the authors proceeded with a
macro and microscopic analysis of anastomoses, besides dos-
ing some cytokines by immunohistochemistry. In this study,
there was no difference in anastomosis bursting pressure,
as well as in septic complications in animals exposed to IFX
versus controls. Additionally, the authors found an increased
expression of TGF-beta1, MMP2  and collagen V in those ani-
mals previously exposed to IFX, showing less inﬂammatory
activity and increased tissue remodeling, but without clinical
consequences for the animals.35
Two recent studies have tried to analyze similar aspects,
but in rabbit experimental models. Frostberg et al., in anas-
tomoses performed in 30 rabbits (15 with a single dose of
IFX 10 mg/kg) found no difference between groups in terms of
tensile strength to break the suture lines.36 In another exper-
imental study from Denmark, Jensen et al. showed opposite
results. In 32 operated rabbits, these authors veriﬁed that less
tensile strength would be used to break the anastomoses in
rabbits previously exposed to IFX (1.94 ± 0.44 N in IFX group
versus 3.33 ± 0.39 N in placebo group, p < 0.001).37 The results
of the main experimental studies on this subject are detailed
in Table 3.
Final  considerations
In short, the controversy about the real impact of biological
agents per se on the postoperative outcomes of abdominal
surgery with resection in CD patients still persists.38 There is
a signiﬁcant diversity in methodologies used in reviewed ret-
rospective studies and in meta-analyses published. The only
prospective study on the subject suggests that patients with
higher serum levels of IFX could present higher rates of post-
operative complications, but the sample of patients in each
subgroup was small. Many  studies intermingled CD with ulcer-
ative colitis patients; this may also have implied some bias to
their respective results. Some studies focused on overall com-
plications, others only in infectious complications, and evenective 21 Lower tensile strength to break
anastomoses
others exclusively on surgical complications, which prevent a
detailed conclusion on the subject. A controlled, multicenter,
prospective study called PUCCINI trial is currently being con-
ducted in the United States.39 It is expected that more  solid
answers will be obtained in a study like this, more  robust and
with a higher level of evidence. Associated factors such as pre-
vious use of corticosteroids and malnutrition should always be
considered in patients using biological therapy before abdom-
inal surgical procedures in CD patients. An individualized
decision on the type of procedure and on the best timing for
its execution should be taken; the surgeon must study the sit-
uation as a whole, not considering only the type of medication
used by the patient.
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